Translational Research in Pediatrics III: Bronchoalveolar Lavage abstract The role of flexible bronchoscopy and bronchoalveolar lavage (BAL) for the care of children with airway and pulmonary diseases is well established, with collected BAL fluid most often used clinically for microbiologic pathogen identification and cellular analyses. More recently, powerful analytic research methods have been used to investigate BAL samples to better understand the pathophysiological basis of pediatric respiratory disease. Investigations have focused on the cellular components contained in BAL fluid, such as macrophages, lymphocytes, neutrophils, eosinophils, and mast cells, as well as the noncellular components such as serum molecules, inflammatory proteins, and surfactant. Molecular techniques are frequently used to investigate BAL fluid for the presence of infectious pathologies and for cellular gene expression. Recent advances in proteomics allow identification of multiple protein expression patterns linked to specific respiratory diseases, whereas newer analytic techniques allow for investigations on surfactant quantification and function. These translational research studies on BAL fluid have aided our understanding of pulmonary inflammation and the injury/repair responses in children. We review the ethics and practices for the execution of BAL in children for translational research purposes, with an emphasis on the optimal handling and processing of BAL samples. Pediatrics 2014; 134:135-154 There is a lack of literature addressing the performance of bronchoalveolar lavage (BAL) in children for research purposes. Published reviews focus on adult populations 1, 2 or on the technical and procedural aspects of performing clinically indicated BAL. [3] [4] [5] In this review, our third in a series on tissue sampling and biobanking for child health studies, 6, 7 we aim to expand on the 2000 European Respiratory Society Task Force for BAL in children, 8 with a particular emphasis on BAL for pediatric translational research. We present the ethical considerations and methodologic issues for obtaining BAL samples for research purposes and review the processing and storage of BAL samples to allow for reliable and reproducible measurements. We also highlight studies that isolated specific cellular and noncellular components from BAL, including newer reports using sophisticated analytic techniques for investigating proteins and surfactants.
The procurement of BAL samples by using flexible bronchoscopy (FB) is a skilled procedure that requires special training to achieve proficiency and ensure patient safety. 4 FB can be performed with variable methods as outlined in Table 1 . Pediatric FB and BAL are generally considered safe and well tolerated [9] [10] [11] [12] ; however, they are technically invasive procedures and carry associated risks in ,2% of patients, including bleeding, barotrauma, need for prolonged intubation, severe hypoxia, and/or bronchospasm. Minor desaturations and epistaxis can occur more frequently in up to 7% of patients, and an additional 19% can experience postbronchoscopy fever. 3 Relative contraindications to FB or BAL include massive hemoptysis, bleeding diathesis, severe airway obstruction, foreign body removal, [12] [13] [14] severe hypoxia, and unstable hemodynamic status. 4 
ETHICS OF PERFORMING BAL FOR RESEARCH
Although complications from FB and BAL are relatively minor and rare, in some institutions the ethics of performing BAL for research purposes are being increasingly scrutinized, likely due to greater awareness of ethics guidelines regarding research studies in children, particularly those studies involving invasive procedures. 15 Institutional ethics review and informed consent by the legal guardians of children undergoing BAL for research studies must be obtained before performing such stud-ies. Assent may be required from adolescent patients. The consent process must ensure that children/families are not coerced into study participation for perceived clinical benefit. 16 Given the ethical considerations in obtaining control BAL fluid for research studies, sample procurement is generally limited to those subjects in whom FB is being performed for a specific clinical indication ( Table 2) [17] [18] [19] [20] [21] [22] [23] [24] [25] or in those whom sedation and intubation is clinically indicated for other reasons (eg, elective abdominal surgery). 26, 27 In the former, control data consist of BAL samples in children without the respiratory disease under investigation. Although the use of these samples may not represent ideal controls, they may be an acceptable alternative for practical considerations in the absence of an acute infectious process and active inflammation on direct visualization of the airways. Even in healthy subjects, perioperative stress may influence levels of inflammatory cells, cytokines, and chemokines in lavage samples. 28 Reference data for BAL cellular constituents in children have been published, [29] [30] [31] [32] [33] [34] [35] [36] but because of wide variability across studies, reference values for BAL cellular and noncellular Lack of full control of airway 39 If conscious sedation is used, apply topical plain lidocaine (2% to 4%) at larynx and 0.5% to 1% at carina to maximum dose of 5-7 mg/kg 39 Allows larger bronchoscope size 39 Allows best visualization of dynamic airway motion 39 Mouth (laryngeal mask airway) 39, 106 Allows inspection of larynx and upper trachea 39 Lack of full control of airway 39 If conscious sedation is used, apply topical plain lidocaine (2% to 4%) at larynx and 0.5% to 1% at carina to maximum dose of 5-7 mg/kg 39 Allows largest bronchoscope size 39 Less ideal for visualization of dynamic airway motion due to distortion of upper airway dynamics Mouth (ETT) 39 Best airway protection 39 
BAL PROCEDURE
Performing BAL involves passing a flexible bronchoscope distally into an airway until the tip becomeswedged and cannot move any farther. 4 The location of BAL sampling is dependent upon the clinical indication, but in cases of diffuse lung disease or for samples acquired for research purposes sampling of the right middle lobe may be ideal from an operator standpoint. 37 It is important to note that the outer diameter of the bronchoscope relative to the wedge position can influence epithelial lining fluid (ELF) recovery and composition; wedging a small bronchoscope into a more distal bronchus will sample a smaller lung volume than if a larger bronchoscope is used.
In certain instances only nonbronchoscopic, blind BAL can be performed, such as in clinically unstable patients and in very small infants for whom the endotracheal tube size precludes insertion of a bronchoscope smaller than 2.7-mm external diameter. Different methods for nonbronchoscopic BAL are described, including the blind insertion of an 8F catheter as far as possible down the endotracheal tube beyond the estimated site of the carina to instill and withdraw fluid in variously sized aliquots, 3, 38, 39 or fixing a catheter to the external surface of a 2.2-mm flexible bronchoscope that does not contain an internal suction channel.
Different methods for determining BAL instillation volume have been reported (Table 3 ) and adjusting the amount of instilled fluid per the weight of the child (aged 3-15 years) was shown to improve the consistency of ELF sampling. 40 Distal sites may be better represented by a higher number of sequential aliquots taken from a particular wedge location. 41 It is not known whether the method of aliquot aspiration affects BAL composition. Two reported methods for aliquot aspiration include the following: mechanical aspiration using 25 to 200 mm Hg pressure (3.33-13.3 kPa) into a suction trap or hand suction using a syringe.
FACTORS AFFECTING COMPOSITION OF BAL FLUID
Many factors can influence the quality and composition of BAL samples, including the total volume of saline instilled and the length of the dwell time between saline instillation and withdrawal, because ELF can be diluted by fluid exchange occurring between alveolar, vascular, and interstitial compartments. 42, 43 The BAL sample should be considered adequate if there is .40% recovery of instilled fluid, ,5% epithelial cells (unless an airway sample is desired), and minimal amounts of mucus after filtering. 5, 8, 28 There is no reliable indicator to calculate the proportion of BAL fluid that represents ELF, which makes comparison between research studies difficult. 1 The concentrations of urea 18, [44] [45] [46] and albumin 47, 48 have been used to estimate the 111 Adjusted by FRC 5 mL for infants 4 N/A 10 mL for small child 4 15 mL for large child 4 3 mL/kg 3, 30, 112 Divided into 3 aliquots for children ,20 kg Divided into 20-mL aliquots for children .20 kg ELF component, although each has its unique problems. Urea is present in ELF in equal concentrations to serum but diffuses into BAL fluid in a timedependent manner, 49 with higher concentrations observed in diseases with increased capillary permeability. Albumin diffuses only very slowly into BAL fluid, but its concentration is frequently altered by lung disease. Given the technical variations used for performing BAL sampling in children, the solute concentrations from BAL are best reported along with the following variables: total volume of normal saline instilled, the number of specimens, the volume of each specimen, the percentage of BAL fluid recovered (eg, number of recovered cells per milliliter of BAL fluid), as well as the site of BAL collection.
BAL FLUID HANDLING AND PROCESSING
General recommendations on BAL in children have been published. 8 Specific recommendations were proposed to optimize the handling and processing of samples to facilitate pathologic diagnosis, but less attention has been paid to the handling and processing of BAL fluid in the context of research practices. [50] [51] [52] Because of the limited ability to perform pediatric FB strictly for research purposes, protocols by which samples are processed and handled will be dependent upon a number of factors and tailored on a "case-by-case" basis, including (1) the primary indication for the procedure, (2) immediate testing to be performed on samples to facilitate diagnosis, (3) local practices, and (4) availability of local resources. Furthermore, given the lack of control data, uniform handling, processing, and storage of samples should be observed to maximize the consistency and minimize variability in the results. Practices for the handling and processing of specimens that are designated for research purposes are summarized in Tables 4 and 5 .
INITIAL PROCUREMENT CONSIDERATIONS
Upon retrieval of BAL fluid, the conditions for fluid transportation are primarily dependent on the anticipated duration of time from sample collection to laboratory analysis. Accordingly, the volume, location, quality of lavage, as well as underlying disease pathology may result in lavage fluid samples that vary considerably between individuals. For BAL samples in which the anticipated When total cell count is performed, filtration of pooled aliquots is important to prevent mixing of mucus with the cell pellet and to remove bronchial epithelial cells 8, 115 Microbiologic studies (cultures) should be performed on unfiltered BAL fluid because organisms may be trapped in the mucus 8 Time to do total cell counting Immediately after collection 113
Time to centrifugation
Samples must be fresh and processed immediately after collection 62, 113 Same as noncellular components When delay in cellular analysis is expected, the BAL sample should be centrifuged at 200-300 g for 10 min, and pellet should be resuspended in nutrientsupplemented media and stored at 4°C for up 12 h 54 Centrifugation step The lavage sample is initially centrifuged at 250-500 g for 10 min at 4°C to separate the pellet (cellular components) from the supernatant (total surfactant or noncellular components) 8
Same as noncellular components
Time to freeze Immediately after centrifugation 113 Cells can remain viable in BAL fluid at 25°C for up to 4 h 114, 115 or at 4°C for up to 24 h 54 Storage
270°C is recommended to maximize storage duration without changes in sample quality 8, 113, 116 Pelleted cells can be resuspended in nutrient-supplemented media and stored at 4°C for up 12 h 54 Freeze-thaw Freeze-thaw should be limited to only 1 cycle to ensure sample integrity 8 Same as noncellular components RT, room temperature (21°C). time for processing is ,60 minutes, samples can be transported "fresh" at room temperature (21°C). 53 After 60 minutes, there is no formal consensus. In general, specimens should be transported on ice and may be stored at 4°C for up to 24 hours. 54 If delays in cellular analysis are expected, samples should be centrifuged at 200 to 300 g 3 10 minutes (to maintain cellular integrity), the cellular fraction should be resuspended in nutrient-supplemented media (eg, Minimum Essential Medium [MEM] supplemented with the pH buffering agent hydroxyethyl piperazineethanesulfonic acid [HEPES]), and the suspension can be stored at 4°C for up to 12 hours. 54 Freeze/ thaw cycles of samples should be avoided when possible.
Processing of cellular components and/ or microbiologic agents should follow guidelines as previously described for freshly obtained clinical samples. When proteins and/or nucleic acids studies are required, BAL fluid supernatants can be stored from -20°C 55 to -80°C 8,56-58 to avoid degradation and then can be bulk analyzed at a later time.
INITIAL ALIQUOT
As a general consideration, the initial BAL fluid aliquot should not be used for direct assessment of the alveolar environment. 41 Although there is no specific consensus regarding the quality of the initial aliquot, previous studies performed in pediatric patients have established that this first sample has a lower cellular yield and may increase the likelihood of airway sampling rather than alveolar sampling. 59 Thus, the initial aliquot may be of greater interest in the study of airway-related diseases. Subsequent BAL samples have higher cell counts and tend to remain consistent across multiple lavages. 59, 60 
MICROBIOLOGIC STUDIES
Occult or suspected respiratory infection represents one of the most common clinical indications for FB and may include bacterial, fungal, and viral pathogens in both immunocompetent and immunocompromised patients. 61 Accurate pathogen identification is also critical to investigate host response. Some advocate that microbiologic studies be performed on nonfiltered BAL samples to eliminate the possibility of inadvertently trapping organisms. 8 Samples sent for microbiologic culture should be processed immediately to minimize the risk of contamination or degradation of anaerobic organisms, and the concurrent use of antibiotics should be noted, which may affect the interpretation of results. 62 Cleaning and disinfection of all instruments used for the BAL procedure should be practiced to minimize the risk of false-positive results. 12, 63, 64 Similarly, avoidance of suctioning while the bronchoscope is in the upper airway is critical to avoid contamination of lower airway samples. 4 Specimens should be collected in leak-proof containers and transported in sealed plastic bags. If delays are anticipated in the processing of samples, refrigeration is preferable to storage at ambient temperatures; delays .48 hours are undesirable and results should be interpreted with caution. 54 
CELLULAR ISOLATION
Sequential aliquots ofBAL fluid shouldbe pooled and filtered through 1 layer of sterile gauze to remove excess mucoid debris 8 ; however, filtering of BAL fluid through gauze may result in a significant reduction in the volume of sample. 65 Furthermore, filtering may result in lower cell counts, in particular adherent alveolar macrophages. 66, 67 Nevertheless, the total volume of retrieved BAL sample should be measured and cell viability should be initially assessed by using standard techniques such as trypan blue staining. 68 Samples should then undergo centrifugation at 50 to 500 g for 10 to 15 minutes for cell subtype isolation and identification, and cell counting should be performed (ie, using cytospin preparations [Diff-Quick staining; Merz & Dade AG, Dudingin, Germany]) by using manual counts on simple smears or through automated counting techniques using a flow cytometer. 29, 69, 70 Table 6 lists specific cellular components that can be isolated from BAL fluid and special considerations for processing.
A minimum of 300 to 350 cells should be counted to maximize accuracy, and multiple slides may be stored for 68 Morphologic changes can be seen in alveolar macrophages that include a foamy appearance in HP, markedly vacuolated cytoplasm with positive staining of vacuoles for fat in chronic aspiration pneumonitis, cytoplasmic inclusions associated with viral infection, ingested RBCs and RBC fragments and hemosiderin with DAH, ingested asbestos bodies, or other dust particles 68 Esterase staining distinguishes immature macrophages from lymphocytes 120 BAL macrophages may exhibit the same light scatter profile as lymphocytes, promoting errors in lymphocyte counts 121 Macrophages can be further characterized through flow cytometric techniques by using monoclonal antibodies 122 In DAH, alveolar macrophages will stain for iron (hemosiderin) if the onset of hemorrhage has preceded the time of BAL by 24-48 h 68, 123 A high-lipid-laden macrophage index 124 may indicate chronic aspiration of oral or gastric contents [125] [126] [127] Immunostaining is used to assess for phagocytosis or apoptosis in asthma 18 KP-1 stains macrophages, which sometimes can be confused with epithelial cells 114 Lymphocytes (eg, CD3, CD4, CD8) 5% to 15% of the cells recovered from BAL of normal individuals are lymphocytes 68 ; the subsets of T lymphocytes in the normal adult lung are 75% of CD3 + , 45% of CD4 + , 25% of CD8 + , and ,5% for B cells 121 ; total T-and B-cell counts are similar in children and adults 128 In children, there is an increase in CD8 + subset of T cells in BAL that gives a lower CD4 + :CD8 + ratio than that in adults 128 Increased numbers of lymphocytes recovered in BAL fluid have been reported in diseases including hypersensitivity pneumonitis, sarcoidosis, berylliosis, tuberculosis, various drug-induced lung diseases, asbestosis, some collagen vascular diseases, and HIV infections 129 A high percentage of lymphocytes (.50%) suggests HP or cellular NSIP, whereas a value .25% suggests granulomatous lung diseases (sarcoidosis, HP), NSIP, berylliosis, drug reaction, COP, LIP, or lymphoma 130 Although sarcoidosis involves predominantly CD4 + T cells, HP involves typically lymphocytic alveolitis with a predominance of CD8 + T cells 131 Immunoperoxidase reaction in immunocytochemistry is frequently used to enumerate lymphocyte populations in BAL fluid in patients with pulmonary diseases, but it is time-consuming and the accuracy and reliability of results depend on the number of cells counted and the experience of the observer 121 Lymphocytes can be assessed by using immunofluorescence-labeled monoclonal antibodies and flow cytometry for counting and assessment of polyclonality 20, 115, 132 Lymphocyte phenotype can be further characterized through flow cytometric techniques by using monoclonal antibodies 122 Flow cytometry rapidly counts large cell numbers compared with manual counting, but the heterogeneity of the cellular populations makes analysis difficult and can lead to the exclusion of cells of interest as well as the inclusion of unwanted cells 121 Cytocentrifugation is the best technique to avoid lymphocyte loss; differential counting of cells is performed on air-dried May-Grünwald-Giemsa-or Wright-Giemsa-stained preparations 115, 133 Cytocentrifugation (Cytospin) can underestimate the proportion of lymphocytes by ∼45% compared with a smear of resuspended cells under a glass coverslip 8 Macrophages can be removed before lymphocyte immunophenotyping by adherence to plastic in media such as RPMI 1640 supplemented with serum for 30 min to 1 h, by the magnetic removal of ingested carbonyl iron, with complement-mediated lysis and anti-CD11c, or by passage through a nylon wool column 121 Specific T-cell subset populations can be isolated by rosetting with neuraminidase-treated sheep erythrocytes followed by Ficoll-Hypaque gradient centrifugation 134 
Neutrophils
Less than 3% of the cells recovered from BAL from normal individuals are neutrophils 68 The percentage of neutrophils is higher in BAL fluid from children ,12 mo than children aged 13-36 mo 31 A high percentage of neutrophils (.50%) strongly suggests pneumonia, 126 aspiration pneumonia, lung abscess, or acute lung injury 130 Increased neutrophils in BAL from patients with sarcoidosis has been associated with more progressive disease that is less likely to respond to immunosuppressive therapy 135 Increases in BAL neutrophils have been correlated with disease severity and prognosis for both HP 136, 137 and IPF 138, 139 ARDS is associated with lung neutrophil infiltration and elevated cytokines/chemokines 56 Elevated neutrophil levels are seen in CF, [140] [141] [142] asthma, PCD, PBB, 143 bronchiectasis, measles, and bronchiolitis obliterans 144 and in patients with tracheotomy 104 Neutrophil apopotosis has been studied in children with RDS/ECMO by using Giemsa staining of cytospin preparations 145 Filtration, as a method to obtain differential cell counts, should be avoided for neutrophils due to filter preparations that can underestimate cell number 115 
Eosinophils
Less than 1% of cells recovered by BAL from normal individuals are eosinophils 68 A high percentage of eosinophils (.25%) suggests eosinophilic lung disease, 130 especially EP if the presentation is acute 146 BAL eosinophilia has been linked to more severe disease and worse prognosis in IPF 147, 148 
Granulocytes
Elevated during CF due to inflammatory reaction 142 RBCs RBC proportion is used to evaluate blood contamination in BAL fluid, 149 which is common If DAH is present, RBCs should be identifiable on the cytospin 68 RBC contamination can be removed by using lysis reagents including ammonium chloride, commercial lysing reagents, or mild hypotonic lysis solution 121 The use of lysing reagents to remove RBC contamination could lead to the release of cellular debris and interfere with lymphocyte gating purity 121 clinical or research purposes. 8 If delays are anticipated for specific cellular analysis, cells can be stored at 4°C and analyzed up to 24 hours later without significant changes in the cellular composition or differential cell count, 54 although neutrophil apoptosis with engulfment by alveolar macrophages can commence before 24 hours, and thus samples should be analyzed with minimum delay. 71, 72 
NUCLEOTIDE ANALYSIS
Cellular gene expression studies from BAL samples in pediatric respiratory disease states have also been reported (ie, cytokine mRNA). 35 More commonly, nucleotide analysis has been useful to detect a variety of infectious pathogens localized in different cell types and/or in cell-free compartments of the respiratory tract and to detect increases in the number of specific cell-type populations (lymphocytes, macrophages, neutrophils, etc). Several molecular techniques with high sensitivity and specificity, such as polymerase chain reaction and hybridization, have been used to identify bacteria, 73,74 mycobacteria, 75, 76 fungi, [77] [78] [79] [80] [81] [82] [83] Chlamydia, 57 mycoplasma, 57 and viruses [84] [85] [86] [87] , whereas consensus has not been reached about the value of polymerase chain reaction for fungal detection due to positive results in patients who do not develop the associated disease. [88] [89] [90] Examples of nucleotide analysis used for samples isolated from cell or cell-free compartments are shown in Table 7 .
NONSURFACTANT PROTEIN ANALYSIS
Protein analyses have been used to assess the functional consequences of gene expression and to provide greater insight into protein expression and modification within complex disease states 91 (Table 8) . Recently, there have been significant advancements in proteomics, which analyzes large numbers of proteins in biological tissues with two-dimensional gel electrophoresis, multidimensional liquid chromatography, and/or mass spectrometry. 92, 93 Because of the abundance of high-molecularweight proteins that predominate in the BAL fluid proteome in both diseased and nondiseased states, the detection of less abundant pathologic proteins may be more difficult 94 and thus require special consideration when initially harvesting BAL fluid.
Because of the inherent nature of biological samples, several factors have the potential to interfere with proteomic analysis, including the presence of insoluble substances and biological salts, 95 in addition to the dilute concentrations of proteins that are being measured. The initial centrifugation of samples before direct analysis or storage will initially remove insoluble factors present in the BAL. Subsequently, desalting of BAL samples has been described through a variety of techniques including dialysis, size-exclusion filtering, protein precipitation, 96 or reversephase chromatography, 97 in addition to removal of ubiquitous proteins such as albumin. 98 Techniques such as affinity purification can be used to minimize the dynamic range and enrich the specific protein of interest. 99 Although proteomic analysis has been used across a spectrumof pediatriclung diseases,lackofuniformityexistsacross published studies and has likely contributed to proteomic variability. 99 Currently, no standardized protocols exist for procedural aspects of sample retrieval and, furthermore, a standardized approach to optimizing samples for proteomic analysis has not been clearly defined. Thus, key information such as volume and protein concentration of the initial lavage, the number of freeze-thaw cycles, and methodology used in sample preparation should be carefully documented and reported.
SURFACTANT ANALYSIS
Analysis of the protein-phospholipid surfactant complexes remains an area of particular interest in pediatric respiratory research. Newer techniques allow in-depth analysis of the surfactant system, including quantification of the functional (large aggregate) and nonfunctional (small aggregate) forms and may offer insight into in vivo function ( Table 9 ). Functional large aggregate forms of surfactant can only be retrieved via high-speed centrifugation (pellet), with nonfunctional small aggregate forms retrieved from the remaining supernatant. An alternative method of aggregate separation includes Squamous epithelial cells suggest that the BAL fluid has been contaminated by oropharyngeal secretions, which may reflect operator inexperience in BAL or aspirated upper airway secretions 68 
Langerhans cells
Langerhans cells can be stained with S-100 protein and CD1a antibodies for the diagnosis of Langerhans cells histiocytosis; these 2 antibodies work well in formalin-fixed, paraffin-embedded sections 114 ARDS, acute respiratory distress syndrome; CD, cluster of differentiation; CF, cystic fibrosis; COP, cryptogenic organizing pneumonia (distinctly adult disease); DAH, diffuse alveolar hemorrhage; ECMO, extracorporeal membrane oxygenation; EP, eosinophilic pneumonia; HP, hypersensitivity pneumonitis; ILD, interstitial lung disease; IPF, idiopathic pulmonary fibrosis (distinctly adult disease); LIP, lymphoid interstitial pneumonia; NSIP, nonspecific interstitial pneumonia (distinctly adult disease); PBB, persistent bacterial bronchitis; PCD, primary ciliary dyskinesia; RBC, red blood cell; RDS, respiratory distress syndrome; RPMI, Roswell Park Memorial Institute. equilibrium buoyant density gradient centrifugation. 100 Although both methods have been validated, high-speed centrifugation can be performed on multiple samples in a less labor-intensive manner compared with equilibrium buoyant density gradient centrifugation. 100 The evaluation of surfactant function can be performed through measurements of surface tension by using surfactometers or quantitative Brewster angle microscopy. [101] [102] [103] [104] Standard practices for the handling, processing, and storage of specimens that are designated for surfactant isolation are listed in Table 5 .
CONCLUSIONS
This review summarizes pertinent issues regarding BAL in children for research purposes, including ethical and methodologic considerations forobtaining BAL fluid, and the cellular and noncellular elements that can be obtained by FB. The Cell-free An increase in immunoglobulins and albumin is detected in these diseases [151] [152] [153] Specific antibodies in BAL can indicate infection Fibrosing alveolitis 151, 152 Radial immunodiffusion in agar 151, 152 
Lung transplant
Dye binding assay kits 176 Cell-free
In some cases, radiolabeled 175 and dye-based immunoassays are used 176, 177 Salivary components and mucin can mask detection of hBD-2 and -3
Matrix components (elastin, collagen glycosaminoglycans) 176 and intracellular cytokines (TNF, IL-1b, IL-8, IL-6, IL-1ra) 177 
CF IHC 177
Intracellular cytokines (IFN-g, IL-2, IL-4, IL-5, IL-10) 181 Asthma Flow cytometry after stimulation with PMA and ionomycin Anti-CD4 added to prevent PMA or ionomycincaused reduction in surface expression of CD4 Extra steps including isolation of subpopulations of proteins should be done to increase the yield of proteins using LC-MS/MS proteomic screen 197 Cation exchange chromatography of trypsindigested samples followed by MS/MS analysis is limited by overlap in the proteins, but it has the advantage of high throughput 197 Opsonins, antioxidants, basement membrane proteins, coagulation proteins, and serum acute-phase reactants (ie, S100A8, S100A9, 208 Healthy children 208 Cell-free BAL fluid, chloroform/methanol followed by HPLC Surfactant phospholipid concentrations are higher in children between 3 and 8 y than in older children 208 SP-A 24, 27, 101, 116, 118, 141, 142, 197, 201, 202, [206] [207] [208] [209] [210] [211] [212] [213] [214] [215] Healthy children 206, 208 PAP 24, 216 Acute inflammatory airway disease 25 Chronic bronchitis 27 Mechanical ventilation 101 ALI/ARDS 116, 118, 197, 207, 210 Isolated from BAL supernatant after first centrifugation Immunoblot 24, 25 Chemiluminescence assay 217 Agglutination assay 27 Gel chromatography 27, 212 Mass spectrometry 210 ELISA 101, 116, 118, 141, 142, 188, 210, 211, 214, 215, 218 Western blot 24, 209, 210, 216, 217, 219 Commercial protein assay kit 217 SP-A concentrations are independent of the child' s age 208 CF, pneumonia, and ARDS shift the composition of phospholipids and reduce the amount of SP-A but not SP-B 142,214 Deglycosylation of reacting proteins using recombinant N-glycosidase F 217 SP-B 24, 25, 101, 116, 118, 142, 197, 210, 211, 214, 215, 217 SP-C 24, 25, 101, 118, 215, 217, 219 SP-D 116, 118, 142, 188, [209] [210] [211] 215, 216, 218 Phosphatidylcholine/ phosphatidylglycerol 116, 142, 214, 220, 221 CF 142 Acute bacterial pneumonia 214 ARDS 116, 220 Thromboembolic disease 221 Isolated from BAL supernatant after first centrifugation; a high-speed centrifugation isolation is conducted for further isolation of lipid-protein complex (from cell-free supernatant or pellet)
Phospholipid content can be determined by phosphorus assay of lipid extract of surfactant pellet after high-speed centrifugation 142 For further separation and analysis of different classes of phospholipids, HPTLC can be used 142, 214 Extensive alterations in the biochemical and biophysical properties of surfactant have been described in CF, pneumonia, and ARDS 116, 142, 214 The lipid-protein complexes from lung lavage are not surface-active in ARDS 116, 220 Lipids can also be extracted from BAL fluid by using chloroform/methanol 222 Phosphatidylinositol 116, 142, 214, 220, 221 Sphingomyelin 116, 142, 214, 220, 221 Phosphatidylserine 116, 142, 220 Phosphatidyl-ethanolamine 142, 221 Lecithin 116,220 ARDS 116, 220 Isolated from BAL supernatant after first centrifugation Supernatant is used for analysis of lipids and enzymatic activities High-speed centrifugation is conducted on the first supernatant for the measurement of surface activity of lipidprotein complex Disaturated lecithin is low, but sphingomyelin and phosphatidylserine are elevated in ARDS 116, 220 Additional phospholipids present in the airways that could dilute surfactant and nonsurfactant lipids can originate from outside or within the lung (type II pneumocytes) 220 Napsin 24 PAP 24 Activity assay Cathepsin H 24 PAP 24 Proteolysis by elastase, cathepsin G, or proteinase 3, then gold or silver staining plus Western blot 24, 213 Cathepsin G 213 CF 213 Coupled spectrophotometric reaction 213 Surfactant function 104 Chronic airway inflammation (chronic bronchitis and tracheostomy patients)
Capillary surfactometer after separation of BAL fluid to large surfactant aggregates (LA) and supernatant with inhibitory constituents Function of LA-supernatant recombinations is poor because of protein influx during lavage procedure ALI, acute lung injury; ARDS, acute respiratory distress syndrome; CF, cystic fibrosis; CLD, chronic lung disease; ELISA, enzyme-linked immunosorbent assay; GER, gastroesophageal reflux; HPLC, high-performance liquid chromatography; HPTLC, high-performance thin layer chromatography; IPF, idiopathic pulmonary fibrosis (distinctly adult lung disease); LA, large aggregates; PAP, pulmonary alveolar proteinosis; RDS, respiratory distress syndrome; SP, surfactant protein; VAP, ventilator-associated pneumonia.
